Zura Bio Shares Plunge After Phase 2 Hidradenitis Suppurativa Trial Misses Endpoints

Zura Bio shares plunged after its Phase 2 TibuSHIELD trial of tibulizumab in hidradenitis suppurativa failed to meet primary and key secondary endpoints.